Your browser doesn't support javascript.
loading
2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis.
Iihara, Hirotoshi; Abe, Masakazu; Wada, Makoto; Iino, Keiko; Akechi, Tatsuo; Imamura, Chiyo K; Okuyama, Ayako; Ozawa, Keiko; Kim, Yong-Il; Sasaki, Hidenori; Satomi, Eriko; Takeda, Masayuki; Tanaka, Ryuhei; Nakajima, Takako Eguchi; Nakamura, Naoki; Nishimura, Junichi; Noda, Mayumi; Hayashi, Kazumi; Higashi, Takahiro; Boku, Narikazu; Matsumoto, Koji; Matsumoto, Yoko; Okita, Kenji; Yamamoto, Nobuyuki; Aogi, Kenjiro.
Afiliación
  • Iihara H; Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.
  • Abe M; Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu, Shizuoka, 431-3192, Japan.
  • Wada M; Department of Psycho­Oncology and Palliative Medicine, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-Ku, Osaka, Osaka, 541-8567, Japan.
  • Iino K; School of Nursing, National College of Nursing, Japan, 1-2-1, Umezono, Kiyose, Tokyo, 204-8575, Japan.
  • Akechi T; Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya, 467-8601, Japan.
  • Imamura CK; Advanced Cancer Translational Research Institute, Showa University, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo, 142-8555, Japan.
  • Okuyama A; Graduate School of Nursing Science, St. Luke's International University, 10-1 Akashi-Cho, Chuo-Ku, Tokyo, 104-0044, Japan.
  • Ozawa K; Division of Survivorship, Institute for Cancer Control, National Cancer Center, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
  • Kim YI; Division of Medical Oncology, Yodogawa Christian Hospital, 1-7-50 Kunijima, Higasiyodogawa-Ku, Osaka, Osaka, 533-0024, Japan.
  • Sasaki H; Division of Medical Oncology, Hematology and Infectious Disease, Fukuoka University Hospital, 7-45-1, Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
  • Satomi E; Department of Palliative Medicine, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
  • Takeda M; Department of Cancer Genomics and Medical Oncology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8521, Japan.
  • Tanaka R; Department of Pediatric Hematology/Oncology, International Medical Center, Saitama Medical University, 1398-1 Yamane, Hidaka, Saitama, 350-1298, Japan.
  • Nakajima TE; Department of Early Clinical Development, Kyoto University Graduate School of Medicine, 54 Kawahara-Cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
  • Nakamura N; Department of Radiation Oncology, St. Marianna University, 2-16-1, Sugao, Miyamae, Kawasaki, Kanagawa, 216-8511, Japan.
  • Nishimura J; Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
  • Noda M; Non-Profit Organizaition Sasaeau-Kai "Alpha", 518-7 Kawado-Cho, Chuo-Ku, Chiba, 260-0802, Japan.
  • Hayashi K; Department of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-Shinnbashi Minatoku, Tokyo, 105-8461, Japan.
  • Higashi T; Department of Public Health and Health Policy, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-0033, Japan.
  • Boku N; Department of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, University of Tokyo, 4-6-1 Shiroganedai, Minato-Ku, Tokyo, 108-8639, Japan.
  • Matsumoto K; Division of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-Cho, Akashi, Hyogo, 673-0021, Japan.
  • Matsumoto Y; Non-Profit Organization Ehime Cancer Support "Orange-No-Kai", 3-8-24 Furukawaminami, Matsuyama, Ehime, 790-0943, Japan.
  • Okita K; Department of Surgery, Otaru Ekisaikai Hospital, 1-4-1, Inaho, Otaru, Hokkaido, 047-0032, Japan.
  • Yamamoto N; Internal Medicine III, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
  • Aogi K; Department of Breast Surgery, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemoto-Machi, Matsuyama, Ehime, 791-0280, Japan. aogi.kenjiro.zx@mail.hosp.go.jp.
Int J Clin Oncol ; 29(7): 873-888, 2024 Jul.
Article en En | MEDLINE | ID: mdl-38753042
ABSTRACT

BACKGROUND:

The Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis 2023 was extensively revised to reflect the latest advances in antineoplastic agents, antiemetics, and antineoplastic regimens. This update provides new evidence on the efficacy of antiemetic regimens.

METHODS:

Guided by the Minds Clinical Practice Guideline Development Manual of 2017, a rigorous approach was used to update the guidelines; a thorough literature search was conducted from January 1, 1990, to December 31, 2020.

RESULTS:

Comprehensive process resulted in the creation of 13 background questions (BQs), 12 clinical questions (CQs), and three future research questions (FQs). Moreover, the emetic risk classification was also updated.

CONCLUSIONS:

The primary goal of the present guidelines is to provide comprehensive information and facilitate informed decision-making, regarding antiemetic therapy, for both patients and healthcare providers.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vómitos / Oncología Médica / Antieméticos Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Int J Clin Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vómitos / Oncología Médica / Antieméticos Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Int J Clin Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Japón